Product Description
Nā Kiʻi Kumu
| Product Name: | Semaglutide |
| Helu CAS: | 910463-68-2 |
| Nā Kaulike Molecular: | C187H291N45O59 |
| Molecular Weight: | 4113.58g / mol |
| Wahi Manaʻo: | 34-39 ° C |
| kala like 'ole: | Keʻokeʻo |
| Hōʻoia Kōkua: | E mālama i ka 8°C-20°C, pale mai ka makū a me ka malamalama |
He aha ka Semaglutide?
ʻO Semaglutide kahi glucagon-like peptide-1 receptor agonist i hoʻohana ʻia i nā poʻe me ka maʻi diabetes type 2 i mea hoʻohui i ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi ai i ka mana glycemic.. ʻO Semaglutide kahi mimic GLP-1 i loaʻa ka 94% sequence homology i ke kanaka GLP-1. Hiki iā ia ke hoʻopaʻa i ka mea loaʻa GLP-1 a hoʻāla i ka mea loaʻa e hoʻohaʻahaʻa i ke kō koko ma o ka hoʻonui ʻana i ka hana insulin a me ka hoʻohaʻahaʻa ʻana i ka huna ʻana o ka glucagon ma ke ʻano he agonist receptor GLP-1. Eia kekahi, hiki i ka semaglutide ke hana ma ka digestive tract ma ka hoʻopaneʻe ʻana i ka hoʻokuʻu ʻana o ka ʻōpū e hoʻoulu i ka piha; ma ka lolo ma ke kāohi ʻana i ka ʻai; a ma ka ʻōnaehana holo kaʻa ma ka hoʻoponopono ʻana i ka intima i hōʻino ʻia a me ka hoʻomaikaʻi ʻana i ka hana endothelial.
Pehea e hana ai ʻo Semaglutide?
ʻO ka pauka Semaglutide he agonist o ka glucagon-like peptide-1 receptor. Hoʻonui ia i ka hana ʻana o ka insulin, he hormone e hoʻemi ana i ke kō koko koko, ma o ka hoʻohālikelike ʻana i ka hopena o ka incretin glucagon-like peptide-1 (GLP-1). ʻIke ʻia e hoʻoulu i ka hoʻonui ʻana o nā pancreatic beta cell, nona ke kuleana no ka hana ʻana a me ka hoʻokuʻu ʻana o ka insulin. Eia kekahi, hiki i ka AASraw semaglutide ke hoʻemi i ka hana glucagon, kahi hormone e hoʻoulu ai i ka glycogenolysis (ka hoʻokuʻu ʻana o nā kaʻa i mālama ʻia mai ke ake) a me ka gluconeogenesis (ka hana ʻana o ka glucose hou). Hoʻemi ia i ka ʻai ʻana i ka meaʻai ma ke kāohi ʻana i ka pōloli a hoʻolohi i ka ʻai ʻana i loko o ka ʻōpū, e kōkua ana i ka pohō kaumaha. Kāohi ia i ka ʻai, ka ʻai ʻai, a me ka mālama ʻana i ka momona.
ʻO ka noiʻi ma Semaglutide
①Hoʻolauna
ʻO Semaglutide kahi lāʻau lapaʻau i hana mua ʻia e mālama i ka maʻi diabetes. Eia naʻe, ua loaʻa ka kaulana ma ke ʻano he lāʻau hoʻemi kaumaha ma hope o ka loaʻa ʻana e kōkua pono i ka poʻe e hoʻemi i ke kaumaha, me ka lua o ke kanaka waiwai loa o ka honua, ʻo Elon Musk. I kēia mau lā, ʻo ka haʻawina—-Hoʻokahi-Weekly Semaglutide i nā ʻōpio me ka momona—-i hoopukaia ma ka Nūpepa Lapaʻau o ʻEnelani hou (NEJM) ua ʻike ʻo semaglutide hiki ke kōkua i nā ʻōpio momona e hoʻemi i ke kaumaha a hoʻoikaika i ke olakino naʻau.
②Nā ʻike koʻikoʻi
- ʻO ka poʻe ʻōpio obese i lawe i ka semaglutide i kēlā me kēia pule i ʻike i ka piʻi ʻana o 16.1% i ka helu kino kino (BMI) i kahi hoʻokolohua hoʻokolohua hoʻokolohua honua 3a, i hoʻohālikelike ʻia me ka piʻi ʻana o 0.6% i ka hui placebo.
- ʻO Semaglutide kahi glucagon-like peptide 1 (GLP-1) agonist receptor hiki ke hoʻemi i ka ʻai, ka meaʻai, a me ka ʻai ʻana i ka calorie, e hana pono ai no ka pohō kaumaha.
- Ua hōʻike ʻia kahi hoʻokolohua lapaʻau nui he hopena kupaianaha ka semaglutide ma ke ʻano he lāʻau hoʻēmi kaumaha, me ka hui i mālama ʻia e nalowale ana i ka awelika o 15.3 kg.
- I Iune 2021, ua ʻae ka US Food and Drug Administration (FDA) i ke kūʻai aku ʻana o semaglutide (Semaglutide), kahi lāʻau hoʻemi kaumaha me kahi inoa kālepa o Wegovy.
- Ua ʻike ʻia kahi noiʻi hou ua ʻoi aku ka maikaʻi o ka semaglutide i kahi placebo ma ke ʻano o ka pohō kaumaha a me ka hoʻomaikaʻi ʻana i nā kumu pilikia cardiometabolic i nā ʻōpio obese.
- Ma hope o ka lawe ʻana i ka semaglutide, ua hoʻomaikaʻi ʻia nā mea pilikia o ka maʻi cardiovascular e like me ka ʻāʻī o ka pūhaka, ka helu glucose koko HbA1c, ka nui o ka cholesterol, ka lipoprotein cholesterol haʻahaʻa haʻahaʻa a haʻahaʻa loa, triglycerides, a me nā triglycerides.
- Ua ʻoi aku ka maikaʻi o ke ola o ka hui semaglutide ma mua o ka hui placebo, no ka nui o nā helu hōʻoluʻolu kino.
③Ka hopena
Ua hōʻike ʻia ʻo Semaglutide he lāʻau lapaʻau maikaʻi loa, a ua hōʻike ʻia nā noiʻi hou e pono paha ia no nā ʻōpio momona. ʻOiai pili ka lāʻau lapaʻau me kekahi mau hopena ʻaoʻao o ka ʻōpū, ua ʻike ʻia e hoʻomaikaʻi i nā kumu pilikia cardiovascular a me nā ana o ke ola.
Kumu kumu:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997064/
Nā pono o ka hoʻohana ʻana Semaglutide
ʻO Semaglutide kahi lāʻau lapaʻau maʻamau e hāʻawi ana i ka nui o nā pono no nā poʻe me nā kūlana olakino. ʻO kekahi o nā kūlana maʻamau e hiki ke pōmaikaʻi mai ka hoʻohana ʻana iā AASraw Semaglutide me ka Type 2 Diabetes Mellitus, nā pilikia caidiovascular, obesity, a me Alzheimer's.
①Ke hoʻohaʻahaʻa i nā pae koko koko
ʻO Semaglutide kahi GLP-1 ʻO ka agonist receptor kūpono i ka hoʻohaʻahaʻa ʻana i ke kiʻekiʻe o ka glucose i ke koko i ka poʻe me ka maʻi maʻi type 2 ma o kekahi mau hana. Hoʻoulu ʻo ia i ka huna ʻana o ka insulin, kahi e kōkua ai i ka hoʻoneʻe ʻana i ka glucose mai ke koko i loko o nā sela kahi e hiki ai ke hoʻohana ʻia no ka ikehu. Hoʻopau pū ʻo Semaglutide i ka huna ʻana o ka glucagon, e hōʻemi ana i ka hana glucose e ke ake. Eia hou, hoʻolohi ia i ka hoʻokuʻu ʻana o ka ʻōpū, kahi e hoʻemi ai i ka nui o ke komo ʻana o ka glucose i ke kahe koko ma hope o ka ʻai ʻana.
I loko o nā hoʻokolohua lapaʻau, ua hōʻike ʻia ka semaglutide e hōʻemi nui i nā pae HbA1c, kahi hōʻailona o ka mālama ʻana i ka glucose koko lōʻihi. Ma ka ho'āʻo SUSTAIN-1, ua hōʻemi ka semaglutide i nā pae HbA1c e 1.5% ke hoʻohālikelike ʻia me ka placebo, a ma ka hoʻāʻo ʻo SUSTAIN-10, ua hoʻemi ʻo ia i nā pae HbA1c e 1.8% i hoʻohālikelike ʻia me kahi placebo. Ua hōʻike ʻia ʻo Semaglutide i ka maikaʻi i ka hōʻemi ʻana i nā pae glucose plasma wikiwiki a me nā huakaʻi glucose postprandial.
②E hōʻemi ana i ka pilikia o nā hanana maʻi cardiovascular
Ua hōʻike ʻia ʻo Semaglutide e hōʻemi i ka hopena o nā hanana maʻi cardiovascular nui (MACE) e like me ka make ʻana o ka cardiovascular, nonfatal myocardial infarction, a me ka make ʻole i nā pākeke me ka maʻi diabetes type 2 a hoʻokumu i ka maʻi cardiovascular. Uaʻikeʻia kēia pōmaikaʻi ma nā ho'āʻo SUSTAIN-6 a me PIONEER-6, i hōʻike i ka emi nui o ka MACE me ka lāʻau semaglutide i hoʻohālikelikeʻia me ka placebo. Eia kekahi, ua hōʻike ʻia ʻo Semaglutide e hoʻomaikaʻi i kekahi mau mea pilikia cardiovascular e like me ke kahe koko, lipid profile, a me nā hōʻailona o ka mumū i ka poʻe me ka maʻi maʻi type 2. I ka hoʻāʻo ʻana ʻo SUSTAIN-6, pili ka semaglutide me kahi hōʻemi nui o ke koko systolic a me ka hoʻomaikaʻi ʻana i ka lipid profile, me ka hoʻemi ʻana i ka kolamu holoʻokoʻa, LDL cholesterol, a me nā triglycerides.
③Nalo ke kaumaha
He ikaika ka Semaglutide kaumaha lilo ʻo ia hoʻi i ka poʻe me ka maʻi diabetes. Hana ʻo Semaglutide ma ka hōʻemi ʻana i ka ʻai a me ka lawe ʻana i ka calorie, e alakaʻi ana i ka emi ʻana o ke kaumaha o ke kino. Loaʻa kēia ma muli o kāna mau hopena i ka ʻōnaehana nerve waena a me ka ʻōpū o ka ʻōpū. Hana ʻo Semaglutide i ka hypothalamus, ka mea e hoʻoponopono ai i ka pōloli a me ka māʻona, a hoʻemi i ka makemake e ʻai ma ka hoʻonui ʻana i nā manaʻo o ka piha. Hoʻohui hou, hoʻolohi ka semaglutide i ka hoʻokuʻu ʻana o ka ʻōpū, e hoʻolōʻihi i ka manaʻo o ka piha ma hope o ka ʻai ʻana a hoʻemi i ka makemake e ʻai.
Ua hōʻike nā hoʻokolohua hoʻokolohua i nā pōmaikaʻi o ka pohō kaumaha o semaglutide.Ma ka papahana STEP, i loiloi i ka hoʻohana ʻana i ka semaglutide no ka hoʻokele kaumaha i nā poʻe me ka maʻi maʻi ʻole, ua pili ka semaglutide me ka pohō kaumaha nui i hoʻohālikelike ʻia me placebo. ʻO nā poʻe i loaʻa i ka semaglutide i hoʻokahi pule i kēlā me kēia pule, ua nalowale ka awelika o 15% o ko lākou kaumaha kino ma mua o 68 mau pule, aʻo ka poʻe i loaʻa kahi placebo i nalowale he 2.4%.
I ka poʻe me ka maʻi maʻi type 2, hiki i ka semaglutide ke alakaʻi i nā pōmaikaʻi o ke kaumaha. I ka ho'āʻo SUSTAIN 7, ka mea i loiloi i ka pono a me ka palekana o ka semaglutide i ka poʻe me ka maʻi diabetes type 2, pili ka semaglutide me ka hoʻohaʻahaʻa nui o ke kaumaha o ke kino i hoʻohālikelike ʻia me ka placebo. ʻO ka poʻe i loaʻa i ka semaglutide ua nalowale ka awelika o 4.6 kg, aʻo ka poʻe i loaʻa kahi placebo i nalowale he 1.2 kg wale nō.
④Lapaʻau ʻana i ka hōʻailona maʻi o Alzheimer
Ua hōʻike ʻia nā haʻawina preclinical he nui he mau neuroprotective ka semaglutide e kūʻē i nā plaque amyloid-β i loko o kahi laina cell neuroblastoma kanaka (SH-SY5Y), e hōʻike ana e hiki i ka semaglutide ke hoʻēmi i nā hōʻailona maʻi o Alzheimer. Ua hōʻike pū ʻia nā hiʻohiʻona holoholona he hopena neuroprotective ka semaglutide ma nā ʻano holoholona. Wahi a ka hoʻolaha ʻana o Novo Nordisk, ʻo ka hōʻailona o nā papa semaglutide no ka maʻi o Alzheimer (AD) aia i ka pae lapaʻau. ʻElua mau hoʻokolohua Phase III honua, ʻo EVOKE a me EVOKE plus, ke hoʻomaka nei, a ma kahi o 3,700 mau mea manawaleʻa e manaʻo ʻia e kiʻi ʻia. Hoʻohālikelike kēia haʻawina me kahi placebo, e loiloi i ka maikaʻi o nā papa semaglutide ma ka hana cognitive i nā kumuhana me ka haʻahaʻa haʻahaʻa haʻahaʻa (MCI) a i ʻole dementia haʻahaʻa i hoʻokumu ʻia e AD.
'Ōlelo Aʻo: He kī nui e kūʻai i ka semaglutide mai nā kumu kaulana, iʻole,ʻaʻole hiki iāʻoe ke loaʻa ka maikaʻi maikaʻi o ka semaglutide.Ma keʻano he mea hana a me ka mea hoʻolako semaglutide, manaʻoʻo AASraw e hoʻolako i ka semaglutide maʻemaʻe ma ka honua holoʻokoʻa. Inā loaʻa iā ʻoe nā pono, ʻo AASraw's semaglutide kahi koho maikaʻi loa iā ʻoe.
Nā hopena ʻaoʻao o Semaglutide?
ʻO Semaglutide, e like me nā lāʻau lapaʻau, hiki ke hana i nā hopena ʻaoʻao.
①Eia nā hopena ʻaoʻao maʻamau:
- 'O Nausea
- ʻO ka wai
- Kōkua
- ʻO kaʻehaʻeha
- Pau ka maʻi
- Ka hoʻomau
- Heʻeha
- 'Oloke
- Hoʻoponopono
②E like me nā hopena ʻaoʻao maʻamau akā ʻoi aku ka koʻikoʻi:
- Pancreatitis
- Hypoglycemia (ke koko haʻahaʻa)
- ʻO ka ʻehaʻehā o kaʻeha
- ʻO ka hoʻopiʻi ʻana i ka retinopathy diabetes
- ʻO ka maʻi Gallbladder
- Nā hopena maʻi
- ʻO nā maʻi maʻi thyroid
Nānā: Hiki ke hoʻololi i ka lōʻihi o nā hopena o ka semaglutide ma muli o ke kanaka a me ka paʻakikī o nā hopena ʻaoʻao. I ka hapanui o nā hihia, he manawa pōkole nā hopena ʻaoʻao o ka semaglutide a e hoʻomaikaʻi ʻia i ka hoʻoponopono ʻana o kou kino i ka lāʻau. ʻO nā hopena ʻaoʻao maʻamau e like me ka nausea, ka ʻōpū, ka luaʻi ʻana, ka paʻa ʻana, a me ke poʻo ʻeha e hoʻoholo maʻamau i loko o kekahi mau lā a i hoʻokahi pule. Inā ʻike ʻoe i nā hopena ʻokoʻa a koʻikoʻi paha i ka wā e lawe ana i ka semaglutide, e hele koke i ke kauka. Hoʻohui, kūʻai aku i ka semaglutide me ke kiʻekiʻe kiʻekiʻe mai kahi mea hoʻolako hilinaʻi, e like me AASraw, he mea koʻikoʻi.
ʻO ka Dosage a me ka hoʻokele ʻana o Semaglutide no ka ʻike
Hiki ke ʻokoʻa ke ʻano a me ka hoʻokele o ka semaglutide ma muli o ka hōʻailona no ka hoʻohana. Eia kekahi mau alakaʻi maʻamau:
①Indication: Type 2 Diabetes Mellitus
· Hoʻopili i lalo
He pule 1-4: 0.25 mg / pule
He pule 5 a ma mua: 0.5 mg / pule
√ Inā pono, ma hope o 4 mau pule ma ka 0.5-mg dose, e hoʻonui i ka 1 mg subcutaneously hoʻokahi pule.
√ Inā pono, ma hope o 4 mau pule ma ka 1-mg dose, e hoʻonui i ka 2 mg subcutaneously hoʻokahi pule i kēlā me kēia pule; ʻaʻole ma mua o 2 mg / pule.
· Papa Waʻa
Lā 1-30: 3 mg / lā
ʻO ka lā 31 a ma mua: 7 mg / lā
√ Inā pono, ma hope o 30 mau lā ma ka 7-mg dose, e hoʻonui i ka 14 mg i hoʻokahi manawa i kēlā me kēia lā.
√ Nānā: Mai lawe i ʻelua papa 7-mg no ka loaʻa ʻana o kahi maʻi 14-mg
②Indication: Ka hoʻokele kaumaha maʻamau
· Hoʻopili i lalo
He pule 1-4: 0.25 mg / pule
He pule 5-8: 0.5 mg / pule
He pule 9-12: 1 mg / pule
He pule 13-16: 1.7 mg / pule
Hebedoma 17 a ma mua aku: 2.4 mg / pule (ka nui mālama)
√ E hoʻomaka me ka haʻahaʻa haʻahaʻa a e piʻi mālie i kahi ʻano mālama e hōʻemi i nā hopena ʻino o ka ʻōpū.
√ Inā ʻaʻole hiki iā ʻoe ke ʻae i kahi maʻa i ka wā e piʻi ai, e noʻonoʻo e hoʻopaneʻe i ka piʻi ʻana o ka maʻi no 4 pule.
√ Inā hiki ʻole ke ʻae i ka nui o ka mālama ʻana o 2.4 mg i hoʻokahi pule, hiki ke hoʻemi iki i ka 1.7 mg i hoʻokahi pule i kēlā me kēia pule no ka lōʻihi o 4 pule; ma hope o 4 mau pule, e hoʻonui hou i ka mālama ʻana i ka 2.4 mg i hoʻokahi pule; hoʻopau inā ʻaʻole ʻae ʻia ma hope o ka hoʻāʻo ʻelua.
√ Nānā: Hiki ke ʻokoʻa ke ʻano a me ka hoʻokele o ka semaglutide ma muli o ka hōʻailona no ka hoʻohana ʻana. E hahai i nā kuhikuhi i hāʻawi ʻia e kāu kauka a i ʻole e like me ka mea i hōʻike ʻia ma ka lepili lāʻau. Eia kekahi, e ho'āʻo i kāu mea maikaʻi loa e kūʻai i ka semaglutide maʻemaʻe e hoʻokō i ka hopena maikaʻi loa.
Ma hea e kūʻai ai iā Semaglutide?
ʻO Semaglutide, kahi lāʻau i ʻimi nui ʻia no ka mālama ʻana i ka maʻi diabetes type 2, ua lilo i mea kaulana i waena o nā poʻe maʻi e ʻimi nei i nā hopena kūpono e mālama i ko lākou kūlana. ʻO ka hopena, ua puka mai nā mākeke pūnaewele ma ke ʻano he kahua kūpono no ka poʻe e kūʻai aku i ka semaglutide ma ka pūnaewele. Hāʻawi kēia mau kikowaena kikohoʻe i nā mea kūʻai aku i ka manawa e hoʻohālikelike ai i nā kumukūʻai, heluhelu i nā loiloi, a me ke komo ʻana i nā koho he nui e kūpono i kā lākou pono. Eia nō naʻe, he mea nui i nā mea kūʻai aku e makaʻala i ke kūʻai ʻana i ka semaglutide ma ka pūnaewele, no ka mea, hiki i nā huahana hoʻopunipuni a haʻahaʻa paha ke hoʻololi i ko lākou olakino. Ma ka hana ʻana i ka noiʻi ʻana a me ke koho ʻana i kahi mea kūʻai aku kaulana a hōʻoia ʻia, hiki i nā kānaka ke kūʻai wiwo ʻole i ka semaglutide ma ka pūnaewele a mālama pono i kā lākou maʻi diabetes me ka maʻalahi.
KANAKA ʻO ka manaʻo e hana a hoʻolako i nā mea waena kemika a me nā mea lāʻau lapaʻau ikaika (API), he mea hilinaʻi i ka semaglutide kiʻekiʻe a me nā huahana pili ʻē aʻe. ʻO kā lākou kūpaʻa i ka mana koʻikoʻi a me ka mālama ʻana i nā kūlana ʻoihana e hōʻoia i ka loaʻa ʻana o nā mea kūʻai aku i nā huahana maikaʻi loa no ko lākou olakino a maikaʻi. Ma ke kūʻai ʻana ma AASraw, hiki i nā poʻe e ʻimi ana i ka semaglutide ke hauʻoli i kahi ʻike kūʻai kūpono, palekana, a hilinaʻi hoʻi, ʻoiai e pōmaikaʻi ana i ko lākou ʻike nui a me ka ʻike ma ke kula.
Hōʻike hoʻāʻo Semaglutide-HNMR
He aha ka HNMR a he aha ka HNMR spectrum e haʻi iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka mālama maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala.. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā huila i loaʻa nā pūhui i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Semaglutide-COA
Pehea e kūʻai ai iā Semaglutide mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu WhatsApp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) iā ʻoe i loko o 12 mau hola.
❷E hāʻawi iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala lawe, a me ka lā i manaʻo ʻia e hiki mai ai (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Aihua Li
Keʻena ʻOihana Lapaʻau, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, Kina
2. Tae Suk Lee
Kula o ka Lapaʻau, Ke Kulanui ʻo Sungkyunkwan, Suwon, Gyeonggi 16419, Lepupalika o Korea
3. Saullo Queiroz Silveira MD
Keʻena o ka Anesthesiology, Vila Nova Star Hospital / Rede D'Or - CMA Anesthesia group, São Paulo, SP, Brazil
4. Fabiane Ferreira Martins
Laboratory of Morphometry, Metabolism, and Cardiovascular Diseases, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
Reference:
[1] Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A.Nā hopena o ke kaumaha i hui pū ʻia me ka mālama ʻana iā Semaglutide no nā maʻi me ke kaumaha a i ʻole ka momona.JAMA Netw Open.2022 Sep 1;5(9):e2231982.
[2] Wilding JPH,Batterham RL,Davies M,Van Gaal LF,Kandler K,Konakli K,Lingvay I,McGowan BM,Oral TK,Rosenstock J,Wadden TA,Wharton S,Yokote K,Kushner RF; KANAWAI 1 Hui Haawina.Loaʻa hou ke kaumaha a me nā hopena cardiometabolic ma hope o ka haʻalele ʻana o semaglutide: ʻO ka hoʻonui hoʻāʻo STEP 1.Diabetes Obes Metab.2022 Aug;24(8):1553-1564.
[3] Garvey WT,Batterham RL,Bhatta M,Buscemi S,Christensen LN,Frias JP,Jódar E,Kandler K,Rigas G,Wadden TA,Wharton S; STEP 5 Study Group. Nā hopena ʻelua makahiki o ka semaglutide i nā poʻe mākua me ke kaumaha a i ʻole ka momona: ka hoʻāʻo STEP 5. Nat Med.2022 Oct; 28(10):2083-2091.
[4] Knudsen LB, Lau J. ʻO ka ʻike a me ka hoʻomohala ʻana o Liraglutide a me Semaglutide.Front Endocrinol (Lausanne).2019 Apr 12; 10:155.
[5] Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative maʻi: He Narrative Review.Pharm Res.2022 Jun;39(6 ):1233-1248.
